PD-L1 IHC 28-8 pharmDx interpretation training

PD-L1 IHC 28-8 pharmDx is the first and only FDA-approved PD-L1 test for use in both non-squamous NSCLC and melanoma for OPDIVO® (nivolumab)

The PD-L1 IHC 28-8 pharmDx interpretation training is a comprehensive program with in-depth content and practice cases focused on helping pathologists to:

Understand the role of immune checkpoint pathways
Learn about technical considerations for optimal slide staining results
Learn how to evaluate non-squamous NSCLC or melanoma specimens stained with PD-L1 IHC 28-8 pharmDx

Enhanced non-squamous NSCLC and melanoma training programs with virtual microscope for increased confidence in scoring PD-L1 stained slides.

*NEW*
non-squamous NSCLC Training

Get started now

ALREADY REGISTERED?
LOGIN NOW

*NEW*
Melanoma Training

Get started now

ALREADY REGISTERED?
LOGIN NOW

Intended Use

For in vitro diagnostic use

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed paraffin-embedded (FFPE) non-squamous non small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of tumor cells exhibiting positive membrane staining at any intensity.

PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVO (nivolumab) treatment.

Positive PD-L1 status as determined by PD-L1 IHC 28-8 pharmDx in melanoma is correlated with the magnitude of the treatment effect on progression-free survival from OPDIVO®.